MSN’s Research & Development division stands at the heart of our innovation engine. With the largest API R&D centre in Asia measuring 750,000 sq. ft., our scientific ecosystem brings together deep chemistry expertise, advanced technologies, and a relentless commitment to accelerate healthcare accessibility worldwide.

With 2400+ scientists, we innovate across complex chemistry, emerging platforms, new technologies, and regulatory-driven development ensuring that life-changing medicines reach global patients sooner, safer, and at scale.

Our R&D Strengths

Scale & Scientific Expertise
  • Largest API R&D Centre in Asia(750,000 sq. ft.)
  • 1200+ scientists & engineers across API, FDF, analytical, and platform innovation
  • 500+ APIs developed and counting
  • 40–45 new DMFs filed every year globally
Innovation-Driven Development
  • Early-launch enabling API development
  • Expertise in controlling Nitrosamines, NDSRIs, and GTIs using QbD-led development
  • Strong collaboration between R&D, Manufacturing, and Regulatory
  • Rapid bench-to-market timelines with robust process optimisation
Expanding into New Complex Scientific Platforms
  • Fermentation-based APIs
  • Oligonucleotides
  • Hormones
  • Peptides & other next-gen technologies
  • Iron Carbohydrate Complexes